98%
921
2 minutes
20
Background: Serrated polyposis syndrome (SPS) is associated with an increased risk of colorectal cancer (CRC) and an evolving management approach. The aims of this study were to assess the polyp burden reduction over time, and the incidence of CRC in serrated polyposis patients undergoing community surveillance.
Methods: This is an observational study based on prospectively collected data. A total of 96 SPS patients with no personal history of CRC were prospectively enrolled in a surveillance program under the guidance of a tertiary center. Patients underwent surveillance colonoscopy in multiple centres across New Zealand.
Results: Patients underwent a median of four colonoscopies with a median interval of 15 months over a median follow-up period of 4.8 years. Five of 96 patients (5%) were referred for surgery, and the remaining 91 were managed by colonoscopy alone. In patients referred for surgery, 92% of the surveillance intervals to the fourth colonoscopy had been ≤12 months compared to 33% (P<0.001) in the colonoscopy only group, and all five (100%) had ≥20 pancolonic polyps after four procedures compared with only 5/91 (5%) in those managed by colonoscopy alone. In patients successfully managed by colonoscopy, 86% had <10 pancolonic polyps, >75% no longer had polyps ≥10mm and >90% no longer had proximal serrated polyps ≥10mm after the fourth colonoscopy. No patients were found to develop CRC during the study time period.
Conclusions: Patients with SPS were managed by proactive surveillance colonoscopy in wider hospital settings under tertiary centre guidance, with only 5% requiring surgical management. No CRC was diagnosed in any patient during surveillance.
Download full-text PDF |
Source |
---|
World J Gastrointest Endosc
August 2025
Rural Clinical School, University of New South Wales, Port Macquarie 2444, New South Wales, Australia.
Background: Sessile serrated lesions (SSLs) are premalignant polyps implicated in up to 30% of colorectal cancers. Australia reports high SSL detection rates (SSL-DRs), yet with marked variability (3.1%-24%).
View Article and Find Full Text PDFClin J Gastroenterol
July 2025
Department of Gastroenterology and Hepatology, Yodogawa Christian Hospital, 1-7-50 Kunijima, Higashiyodogawa-ku, Osaka, 533-0024, Japan.
The serrated neoplastic pathway has been reported to be involved in the development of colorectal cancer, and serrated lesions are recognized to have malignant potential. Recently, serrated lesions of the duodenum have been increasingly reported. Serrated polyposis syndrome (SPS) is characterized by multiple serrated lesions in the colon; however, it is unknown whether serrated lesions in the duodenum occur in patients with SPS.
View Article and Find Full Text PDFRev Esp Enferm Dig
June 2025
Aparato Digestivo, Hospital Universitario Central de Asturias.
We present the case of a 55-year-old woman with no relevant medical history diagnosed with serrated polyposis following a screening colonoscopy in 2021. In March 2024, a suspicious polypoid lesion was identified in the hepatic flexure. Histological analysis confirmed a poorly differentiated adenocarcinoma.
View Article and Find Full Text PDFInt J Cancer
September 2025
Gastroenterology, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), CIBEREHD, Hospital Clínic Barcelona, Barcelona, Spain.
Serrated polyposis syndrome (SPS) is characterized by multiple and/or large serrated polyps and increased colorectal cancer (CRC) risk. Germline predisposition to SPS is mostly undetermined. We aimed to identify a new inherited SPS predisposition component by functionally evaluating a candidate gene replicated in two independent SPS cohorts.
View Article and Find Full Text PDFVirchows Arch
May 2025
Department of Pathology, University of Chicago Medicine, 5841 S. Maryland Avenue, MC 6101, Room S-638, IL 60637-1470, Chicago, USA.
Only a minority of patients at high likelihood of a gastrointestinal polyposis syndrome (GPS) are appropriately referred for workup. This proof-of-concept study evaluates a GPS screening rubric based exclusively on information in prior pathology reports and intended to facilitate pathologist engagement in GPS screening and referral. We sought to (1) identify patients who would benefit from further GPS workup, (2) assign a probable polyposis syndrome category (adenomatous, hamartomatous, serrated, or mixed), and (3) suggest a specific syndrome, such as familial adenomatous polyposis, whenever possible.
View Article and Find Full Text PDF